Pricing Log in Create free account
Friday 6 November 2026 Export EXEL’s income statement to Excel — free account

Exelixis, Inc.

EXEL Healthcare Biotechnology

Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.

Revenue
+10.2%
EPS
+22.2%
Free cash flow
−4.83%

Quarter to September 2026, against a year earlier

70.06 1.35 +1.96%
Market cap
$16.8B
P/E
19.9×
Fwd P/E
20.2×
Dividend yield
—
F-score
7/9
Altman Z
12.68
Beneish M
−2.61
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Exelixis, Inc. (EXEL) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Exelixis, Inc. (EXEL) trades at a EV/Sales of 6.5×. Over the past ten years it has ranged from 2.0× (October 2022) to 51.3× (August 2015); the current reading is higher than 63% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 4.7× 18.53%
FY2024 4.0× 8.90%
FY2023 3.6× 47.78%
FY2022 2.5× (18.29%)
FY2021 3.0× (40.69%)
FY2020 5.1× 8.91%
FY2019 4.7× (23.28%)
FY2018 6.1× (68.98%)
FY2017 19.5× 11.65%
FY2016 17.5× (54.52%)

Quarterly newest first

Period EV/Sales Change
Sep 2026 5.4× 2.99%
Jun 2026 5.3× 21.17%
Mar 2026 4.3× (7.19%)
Dec 2025 4.7× 5.90%
43 more quarters

Against its own ten years

Low 2.0× High 51.3×
Ten-year median 5.5×
Current reading's percentile 69

EV/Sales against peers

Company EV/Sales
BNTX BioNTech SE Sponsored ADR compare 1.8×
ALNY Alnylam Pharmaceuticals, Inc. compare 3.7×
JAZZ Jazz Pharmaceuticals PLC compare 3.7×
EXEL Exelixis, Inc. 6.5×
HALO Halozyme Therapeutics, Inc. compare 9.0×
ASND Ascendis Pharma A/S compare 13.1×
INSM Insmed, Inc. compare 15.4×
BBIO BridgeBio Pharma, Inc. compare 15.9×
SMMT Summit Therapeutics PLC compare 15,046×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on EXEL